The Paper reporter Yang Yang and Li Xiaoxiao

　　Pien Tze Huang's revenue and net profit in the third quarter both dropped.

　　On the evening of October 21, Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (600436.SH, hereinafter referred to as "Pien Tze Huang"), a "traditional Chinese medicine mao", disclosed its financial report for the third quarter of 2022, and achieved revenue of 2.193 billion yuan during the period, a year-on-year decrease of 3.08%; The net profit attributable to the parent was 738 million yuan, a year-on-year decrease of 17.64%; the non-net profit attributable to the parent was 745 million yuan, a year-on-year decrease of 16.39%.

　　According to the semi-annual report released on August 19, Pien Tze Huang’s revenue in the second quarter was 2.075 billion yuan and net profit was 625 million yuan, a slight drop from the first quarter.

Compared with the latest data, Pien Tze Huang’s revenue and net profit in the third quarter both increased month-on-month, of which net profit increased by about 18% month-on-month.

　　According to Wind, the last time Pien Tze Huang’s single-quarter net profit fell year-on-year was in the fourth quarter of 2016, and the year-on-year decline in revenue was in the third quarter of 2014.

The last time both revenue and net profit declined year-on-year was in the third quarter of 2014.

　　From the perspective of the first three quarters, the overall revenue of Pien Tze Huang was 6.616 billion yuan, and the net profit attributable to the parent was 2.052 billion yuan, an increase of 8.25% and 2.04% year-on-year.

The increase was down from the same period last year.

In the first three quarters of 2021, Pien Tze Huang’s operating income was 6.112 billion yuan, a year-on-year increase of 20.55%; the net profit attributable to shareholders of listed companies was 2.011 billion yuan, a year-on-year increase of 51.36%.

　　At the same time as the announcement of the third quarter financial report, Pien Tze Huang also announced the main operating data of the first three quarters, showing that the company's main business income in the first three quarters was 6.599 billion yuan.

From the perspective of business sectors, the pharmaceutical manufacturing industry is still the main income of Pien Tze Huang, which is 3.144 billion yuan, and the gross profit rate is the highest, reaching 78.35%. In addition, the pharmaceutical circulation industry, daily chemical industry, and food industry have achieved revenue of 2.862 billion yuan and 4.61 billion yuan respectively. 100 million yuan and 132 million yuan.

　　It is worth noting that in the first three quarters, the gross profit margin of each business segment of Pien Tze Huang showed a downward trend.

In terms of different industries, the gross profit rate of pharmaceutical manufacturing, pharmaceutical distribution and daily chemical industry decreased by 1.87%, 0.21% and 9.39% respectively year-on-year; in terms of products, the gross profit rate of Pien Tze Huang's core product liver disease drugs decreased by 1.58% year-on-year.

From a regional perspective, the main business income in Northeast China fell by nearly 30% compared with the same period last year, while that in Central China increased by 18.18%.

Pien Tze Huang announced that the changes in revenue in various regions in the country were mainly due to changes in sales in the pharmaceutical industry.

　　Pien Tze Huang was established in 1999 and listed on the Shanghai Stock Exchange in 2003. In 2006, it became one of the first batch of "China Time-honored Brands" enterprises recognized by the Ministry of Commerce.

The company's most famous product is the Pien Tze Huang series of products with the same name as the company, of which Pien Tze Huang lozenges are its classic products.

　　Last year, the price of a single tablet of Pien Tze Huang lozenges was once fired to more than 1,000 yuan, and Pien Tze Huang's share price also rose.

"Securities Times" reported in September that in the flagship store of Taobao Pien Tze Huang Pharmacy, 3g*1 capsules of Pien Tze Huang are on sale normally at a price of 590 yuan.

Since September last year, the price of Pien Tze Huang lozenges has been falling. The official guide price of Pien Tze Huang lozenges in 3g*1 capsules is now as low as 400 yuan per capsule.

　　As of the close on October 21, Pien Tze Huang fell 1.5% to close at 257.36 yuan per share, with a market value of about 155.3 billion yuan, which has evaporated more than 140 billion yuan from the highest point last year.